22:41 , Jul 20, 2018 |  BC Extra  |  Company News

Management tracks: Merck KGaA, Aeglea

Merck KGaA (Xetra:MRK) hired Maria Rivas as SVP, head of global medical affairs. She was SVP, head of medical affairs at Merck & Co. Inc. (NYSE:MRK). Enzyme therapy company Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) said interim...
20:45 , May 30, 2018 |  BC Extra  |  Company News

Management tracks: Zafgen, Rigel

Metabolic disease company Zafgen Inc. (NASDAQ:ZFGN) hired Brian McVeigh as CBO. He was VP of worldwide business development transactions and investment management at GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). Immunology and cancer company Rigel Pharmaceuticals Inc. (NASDAQ:RIGL)...
00:27 , Jul 21, 2017 |  BC Extra  |  Company News

Management tracks

Enzyme therapy company Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) said President and CEO David Lowe resigned. Director and former interim CMO Anthony Quinn will be interim CEO while the company seeks Lowe's successor. Neurology and cardiovascular company...
23:37 , Jul 17, 2017 |  BC Extra  |  Company News

Management tracks

Osteoporosis and cancer play Radius Health Inc. (NASDAQ:RDUS) named Jesper Hoiland president and CEO. He was president of the U.S. division at Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO). Gene therapy company Freeline Therapeutics (London, U.K.) appointed...
22:43 , Jul 7, 2017 |  BioCentury  |  Finance

Generalists needed

Following a nearly two-year political overhang on the biotech sector, buysiders believe sentiment once again may be turning positive and starting to catch up with the industry’s positive fundamentals. As evidence, they point to the...
05:08 , Jun 16, 2017 |  BC Week In Review  |  Financial News

Aeglea prices $12.3M follow-on

On June 6, enzyme therapy company Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) raised $12.3 million through the sale of 3 million shares at $4.10 in a follow-on underwritten by JonesTrading Institutional Services. Aeglea BioTherapeutics Inc. (NASDAQ:AGLE), Austin,...
23:51 , May 25, 2017 |  BC Extra  |  Company News

Management tracks

Epigenetics play Constellation Pharmaceuticals Inc. (Cambridge, Mass.) named Jigar Raythatha president and CEO. He was CBO at Jounce Therapeutics Inc. (NASDAQ:JNCE), and was previously Constellation's head of corporate development. Former Constellation CEO Keith Dionne has...
00:18 , May 19, 2017 |  BC Week In Review  |  Clinical News

Aeglea reports Phase I data for AEB1102

In March, Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) reported top-line data from a Phase I trial to treat arginase 1 (ARG1) deficiency showing that IV AEB1102 was well tolerated and reduced blood arginine levels to normal levels....
20:02 , Dec 13, 2016 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Chronic lymphocytic leukemia; breast cancer; prostate cancer Patient samples, cell culture and mouse studies suggest an engineered CTH variant could help treat CLL, breast cancer and prostate cancer. Combinatorial mutagenesis of the active site...
07:00 , Aug 15, 2016 |  BioCentury  |  Finance

Serving returns

China's Ally Bridge Group hit the investment world's radar in 2015 with its audacious move to take CRO WuXi PharmaTech Inc. private. If the firm and its partners can engineer the first fruits of that...